ArticleBMC cancer2010
FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00015587 (Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- FLT3 as a germ line driver in AML: expanding the landscape of leukemia predisposition.Blood neoplasia · 2026Article
- In Utero Origins of Acute Leukemia in Children.Biomedicines · 2024Review
- Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.Genes, chromosomes & cancer · 2019Article
- Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.Oncotarget · 2016Article
- Childhood Leukemia and Primary Prevention.Current problems in pediatric and adolescent health care · 2016Article
- Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis.BMC genomics · 2016Article
- Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.Leukemia · 2015Article
- PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.International journal of cancer · 2014Article
- Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia.Leukemia research reports · 2014Article
- Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.Frontiers in oncology · 2014Review
- Pattern of chromosome involvement in childhood hyperdiploid pre-B-cell acute lymhoblastic leukemia cases from India.Indian journal of human genetics · 2014Article
- Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.Advances in hematology · 2014Article
- FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.Mediterranean journal of hematology and infectious diseases · 2014Article
- Perspectives on the causes of childhood leukemia.Chemico-biological interactions · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMutations in FLT3 result in activated tyrosine kinase activity, cell growth stimulation, and a poor prognosis among various subtypes of leukemia. The causes and timing of the mutations are not currently known. We evaluated the prevalence and timing of origin of FLT3 mutations in a population series of childhood leukemia patients from Northern California.
methodsWe screened and sequenced FLT3 mutations (point mutations and internal tandem duplications, ITDs) among 517 childhood leukemia patients, and assessed whether these mutations occurred before or after birth using sensitive "backtracking" methods.
resultsWe determined a mutation prevalence of 9 of 73 acute myeloid leukemias (AMLs, 12%) and 9 of 441 acute lymphocytic leukemias (ALLs, 2%). Among AMLs, FLT3 mutations were more common in older patients, and among ALLs, FLT3 mutations were more common in patients with high hyperdiploidy (3.7%) than those without this cytogenetic feature (1.4%). Five FLT3 ITDs, one deletion mutation, and 3 point mutations were assessed for their presence in neonatal Guthrie spots using sensitive real-time PCR techniques, and no patients were found to harbor FLT3 mutations at birth.
conclusionsFLT3 mutations were not common in our population-based patient series in California, and patients who harbor FLT3 mutations most likely acquire them after they are born.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.